IL-BRIGHTON-PARK
13.1.2022 12:02:08 CET | Business Wire | Press release
TheMathCompany, a global data analytics and data engineering firm that partners with companies to enhance their analytics capabilities, today announced that it has secured $50 million in investments. The round of funding was led by Brighton Park Capital, an investment firm that specializes in collaborating with growth-stage software, healthcare, and tech-enabled services businesses. Existing investor, Arihant Patni, also participated in this round. The minority investment will accelerate TheMathCompany’s expansion in the US and EU markets, as well as enhance its next-generation, proprietary platform, Co.dx, which drives value for businesses through analytics at speed and scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220113005153/en/
Founded by industry leaders, Sayandeb Banerjee, Aditya Kumbakonam, and Anuj Krishna, TheMathCompany is a high-growth firm that employs nearly 1,000 data scientists, data engineers, and domain experts. The company represents and partners with Fortune 500 customers across the CPG, Retail, Pharma, Automotive, Technology, and Manufacturing industries in the US, UK, and EU. Enabling clients with a diverse set of capabilities powered by Co.dx, the organization implements data science and engineering initiatives across business functions, including marketing, supply chain, R&D, and finance. TheMathCompany’s hybrid model unifies Co.dx with a comprehensive consulting approach to deliver custom, cutting-edge analytics and AI-driven assets, helping customers implement successful and strategic business decisions.
“ We are thrilled to announce Brighton Park Capital’s investment,” said Sayandeb Banerjee, CEO of TheMathCompany. “The firm’s deep technology sector expertise and proven track record of scaling global enterprises will be instrumental to our growth.”
“We look forward to partnering with TheMathCompany’s founders and the entire team to support their continued growth,” said Mark F. Dzialga, Managing Partner of Brighton Park Capital. “TheMathCompany is positioned for continued success as it strengthens its brand recognition and expands in the US and EU markets, supporting customers on their missions to capture value through data analytics.”
“TheMathCompany is poised to become one of the largest data and analytics consultancies in the world, supported by a world-class team of data engineers and scientists, and complemented by the power of the Co.dx platform to deliver more value, faster, for customers. I couldn’t be more excited to partner with Sayandeb, Aditya, and Anuj on the significant opportunities ahead,” said Jeff Machlin, Partner of Brighton Park. As part of the transaction, Jeff Machlin will join the Board of Directors.
“While most players in the industry have taken decades to grow to our size, we have built this strong foundation within five years. Brighton Park Capital’s partnership will further accelerate our plans to become the world’s leading global analytics consultancy,” said Aditya Kumbakonam, Chief Customer & Growth Officer at TheMathCompany. “As we grow and evolve, this investment will help us continue to bring elevated service and consistent quality to our customers.”
Anuj Krishna, Chief Product Officer at TheMathCompany, said, “With Brighton Park Capital as investors, we are excited to continue creating better opportunities for our people to grow their careers, while expanding the business globally. TheMathCompany will continue to invest heavily in Co.dx – a significant and meaningful differentiator in our journey to help enterprises scale and solve problems faster.”
TheMathCompany employs leading data scientists and engineers globally while also recruiting emerging talent from top-tier universities. New hires participate in a comprehensive onboarding and training program with the company’s in-house growth accelerator, Co.ach. The program is designed to help employees upskill across analytics disciplines and adapt to the industry’s ever-changing dynamics. In addition to fostering continued career development, the firm incentivizes employees with a stock ownership program, enabling them to participate in TheMathCompany’s continued growth and future success.
Avendus Capital served as financial advisor and Shardul Amarchand Mangaldas & Company served as legal counsel to TheMathCompany. Bharucha & Partners and Paul Weiss served as legal counsel to Brighton Park Capital.
About TheMathCompany
TheMathCompany is a global data analytics and data engineering firm that partners with Fortune 500 and equivalent organizations to enhance their analytics capabilities, using IP-led assets, talent, and processes to deliver accelerated and human-centric solutions. TheMathCompany has been recognized as one of the fastest-growing analytics firms in the world and has been featured among global high-growth firms by Nikkei-FT-Statista’s 2021 Growth Champions list, NASSCOM’s AI Gamechangers 2021 report, and the Everest Group’s PEAK Matrix® Assessment 2021. Providing a holistic range of services across data engineering, science, and unique project delivery, the company is disrupting the analytics industry. For more information about TheMathCompany, please visit www.themathcompany.com .
About Brighton Park Capital
Brighton Park is a Greenwich, CT-based investment firm that specializes in software, healthcare, and technology-enabled services. The firm invests in companies that provide highly innovative solutions in partnership with great management teams. Brighton Park brings purpose-built value-add capabilities that match the unique requirements of each of its companies. For more information about Brighton Park, please visit www.bpc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220113005153/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom